MediciNova Takes a Big Step in the Fight Against COVID-19

By Chris Lange Published Sep 23, 11:09AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

MediciNova Takes a Big Step in the Fight Against COVID-19 — © dra_schwartz / E+ via Getty Images

MediciNova Inc. (NASDAQ: MNOV) has announced progress in its COVID-19 vaccine prototype, which stands out from the rest as it is administered intranasally. The company’s shares jumped on Wednesday as a result.

Specifically, the firm announced that its intranasal SARS-CoV-2 vaccine prototype for COVID-19, using BC-PIV technology, successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen of SARS-CoV-2 in mice.

These successful results support the scientific and technical rationale of the intranasal vaccine, in addition to similar success with BioComo’s BC-PIV RSV vaccine prototype.

The vaccine prototype has proven highly efficient in its ability to transfer multiple foreign proteins to recipients. It also has a strong safety profile as no secondary infectious virus was produced.

[nativounit]

BC-PIV is designed to display not only the gene but also the foreign protein itself on the surface and inside of the viral membrane. Therefore, it can carry the large membrane proteins of viruses and signal transduction receptors/ligand proteins on the viral surface. The BC-PIV SARS-CoV-2 vaccine prototype has been developed to include the specific SARS-CoV-2 antigen protein in order to express maximum antigenicity.

Management stated that it was very encouraged by the intranasal vaccine and the results from the mouse model study. Again management is looking forward to reporting additional progress on its intranasal COVID-19 vaccine in the near future.

Excluding Wednesday’s move, MediciNova stock had underperformed the broad markets with about an 18% year-to-date retreat. In the past 52 weeks, the share price was down closer to 29%.

MediciNova stock traded up about 14% on Wednesday, at $6.33 in a 52-week range of $2.79 to $13.25. The consensus price target is $18.50.

[recirclink id=768967][wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.